The Potential Role of Hyperbaric Oxygen Therapy in Psoriasis Treatment: A Review of PI3K/AKT/FOXO Signaling Cascade and Interleukin-1β
Main Article Content
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disorder that affects 2-3% of the population worldwide. Current therapies, including biologic agents, often have adverse effects and incomplete efficacy. Recent studies suggest that the PI3K/AKT/FOXO signalling cascade and interleukin-1 β play a crucial role in the pathogenesis of psoriasis. Hyperbaric oxygen therapy, a safe and well-tolerated procedure, has been suggested as a potential treatment for psoriasis due to its ability to increase tissue oxygenation and reduce inflammation. This review article summarizes the current understanding of the pathophysiology of psoriasis and the potential benefits of hyperbaric oxygen therapy as a treatment modality. The authors suggest that hyperbaric oxygen therapy may modulate the PI3K/AKT/FOXO signalling cascade, reduce interleukin-1 β levels, and improve skin oxygenation, leading to the attenuation of psoriatic plaques. Further clinical studies are needed to confirm the safety and efficacy of hyperbaric oxygen therapy in psoriasis treatment.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. (2018) 9:579.
II. Boehncke WH, Schon MP. Psoriasis. Lancet (2015) 386:983–94. 10.1016/S0140-6736(14)61909-7
III. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. . Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 449:564–9.
IV. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, et al. . Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. (2009) 129:79–88.
V. Boehncke WH, Brembilla NC. Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy Immunol. (2017) 55:295–311.
VI. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. (2013) 34:174–81.
VII. Zhang M, Zhang X. The role of PI3K/AKT/FOXO signaling in psoriasis. Arch Dermatol Res. 2019 Mar;311(2):83-91. doi: 10.1007/s00403-018-1879-8.
VIII. Nywana Sizemore,1 Stewart Leung,2 and George R. Stark1,*) Activation of Phosphatidylinositol 3-Kinase in Response to Interleukin-1 Leads to Phosphorylation and Activation of the NF-κB p65/RelA Subunit (Mol Cell Biol. 1999 Jul; 19(7): 4798–4805.
IX. Mason J, Mason AR, Cork MJ: Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002, 146:351-364.
X. Ashcroft DM, Po AL, Williams HC, Griffiths CE: Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000, 320:963-967.
XI. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA: Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003, 48:760-767.
XII. Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J: Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998, 39:590-596.
XIII. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr: A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003, 9:2.
XIV. Naldi L, Rzany B: Chronic plaque psoriasis. Clin Evid 2004, 11:2140-2167.
XV. Boehncke WH, Prinz J, Gottlieb AB: Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006, 33:1447-1451.
XVI. Al-Waili N, Butler G: Effects of hyperbaric oxygen on inflammatory response to wound and trauma: possible mechanism of action. Scientific World Journal 2006, 6:425-432.
XVII. Al-Waili N, Butler G, Petrillo RL, Carrey Z, Hamilton RW: hyperbaric oxygen and lymphoid system function: a review supporting possible intervention in tissue transplantation. Technol Health Care 2006, 14:489-498.
XVIII. Chen H, Wu G, Sun Q, Dong Y, Zhao H. hyperbaric oxygen protects mandibular condylar chondrocytes from interleukin-1β-induced apoptosis via the PI3K/AKT signaling pathway. Am J Transl Res. 2016 Nov 15;8(11):5108-5117. PMID: 27904712; PMCID: PMC5126354.
XIX. Gottlieb S, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1:442-446.
XX. Krueger J: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46:1-23.
XXI. Kudchodkar B, Wilson J, Lacko A, Dory L: hyperbaric oxygen reduces the progression and accelerates the regression of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2000, 20:1637-1643.
XXII. Lukich V, Poliakova L, Sotnikova T, Belokrinitskii D: hyperbaric oxygenation in the comprehensive therapy of patients with rheumatoid arthritis (clinico-immunologic study) [in Russian]. Fiziol Zh 1991, 37:55-60.
XXIII. Brenner I, Shephard R, Shek P: Immune function in hyperbaric environments, diving, and decompression. Undersea Hyperb Med 1999, 26:27-39.
XXIV. Benson M, Minter M, Osborne B, Granowitz E: hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages. Liver Transpl Surg 2003, 134:57-62.